



(', 1995 International Society for Neurochemistry
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Abstract : Dopamine receptors belong to the seven trans-
membrane helix-containing, G protein-coupled receptor
superfamily . Mutagenesis studies suggest that dopamine
and its analogues interact with aspartate-114 in helix 3
and two helix 5 serines (194 and 197) of the D2 receptor .
In addition to these amino acids, hydrophobic residues
within the receptor core may be important not only for
binding but also for receptor activation . Described is a
site-directed mutagenesis investigation into the roles of
these hydrophobic residues in the long isoform of the
human D2 receptor . Replacement of helix 6 phenylala-
nines (389 or 390) with alanines resulted in disrupted
binding to several agonists and antagonists and impaired
inhibition of adenylyl cyclase activity . Replacement of the
helix 5 phenylalanine-198 with an alanine selectively dis-
rupted [ 3H]N-0437 binding, whereas the affinities for
other agonists and antagonists remained unchanged .
This mutant remained functionally intact when stimulated
with dopamine or bromocriptine . Replacement of the he-
lix 7 phenylalanine-411 or the helix 6 leucine-387 with
alanines produced receptors that bound agonists well but
were unable to inhibit adenylyl cyclase . Based on these
data, two conserved helix 6 phenylalanines (389 and 390)
appear to be crucial for ligand binding, and phenylala-
nine-411 in helix 7 and leucine-387 in helix 6 may be
important for propagating conformational changes from
the agonist binding site(s) to G protein coupling do-
main(s) of the D 2 receptor. Key Words : Site-directed
mutagenesis-Phenylalanine-Coupling -Seven trans-
membrane helix-containing receptors .
J . Neurochem . 65, 2105-2115 (1995) .
Molecular biological techniques have led to the
identification of five distinct dopamine receptor sub-
types (D,-S), each encoded by a different gene (for
review, see Sibley and Monsma, 1992) . Hydropho-
bicity plots and analyses of their deduced amino acid
sequences suggest the receptor proteins are members
of the seven transmembrane (TM), guanine nucleofide
binding (G) protein-coupled superfamily of membrane
receptors . Although the nature of ligand varies widely,
the members of this superfamily display high amino
acid homology, and this similarity in primary structure
presumably leads to similar secondary and tertiary
structures .
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The proteins of this superfamily perform at least
two functions : (a) ligand binding and (b) G protein
coupling or signal transduction . It follows that G pro-
tein-coupled receptors can be conceptually and perhaps
spatially divided into a ligand binding domain and a G
protein-coupling domain . Interactions with G proteins
appear to involve the intracellular loops and the car-
boxy-terminus, as evidenced by various mutational
strategies (Strader et al ., 1987a ; Dixon et al ., 1988 ;
Kobilka et al ., 1988 ; O'Dowd et al ., 1988 ; Cotecchia
et al ., 1990) . Depending on the type of ligand to which
the receptor binds, the ligand binding domain may in-
volve extracellular (Fong et al ., 1992) and/or TM
(Dixon et al ., 1987 ; Strader et al ., 1988, 1989) regions .
Receptors of small cationic ligands, such as adrenergic
and dopaminergic receptors, appear to bind ligands at
the TM helices .
Mutagenesis efforts have greatly detailed the bind-
ing "pocket" within the lumen of the transmembra-
nous protein core of the adrenergic receptors . These
studies demonstrate the importance of several con-
served amino acids for binding to the endogenous cate-
cholamine ligands epinephrine and norepinephrine .
Key amino acids include a negatively charged aspartate
in the third TM helix (TM3) and two serine residues
in TM5 (Strader et al ., 1988, 1989 ; Wang et al ., 1991) .
Dopamine receptors, although they bind a different
endogenous catecholamine, also possess these cognate
amino acids ; mutagenesis of these residues in the D2
subtype has produced similar but not identical results .
Mansour et al . (1992) have corroborated the impor-
tance of the TM3 aspartate and revealed potential ago-
nist interactions with two TM5 serines (194 and 197) ;
however, the two serine residues of the Dz dopamine
receptor were not equally important, with serine-197
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being more important for agonist binding . In addition,
ligand binding may also be influenced by serine-193
in TM5 and a TM7 serine (Cox et al ., 1992) . It is
interesting that D, dopamine receptors have four
closely packed serines in TM5 (197, 198, 199, and
202), three of which may be involved in binding with
dopamine (Pollock et al ., 1992) .
Many explorations into seven-TM receptor topogra-
phy have emphasized ligand binding regions, but the
mechanism(s) by which receptor occupancy leads to
receptor activation remains unclear . Recombinant
DNA mutagenesis data, such as those outlined above,
have contributed greatly to the refinement of seven-
TM receptor models built on the framework of the
bacteriorhodopsin three-dimensional structure (Hen-
derson et al ., 1990) . Refinement of these models has
led to detailed speculation about residues that may not
only stabilize binding at the aforementioned key an-
chor points, but that may also play a role in receptor
activation and signal transduction . One such model for
receptors of small cationic molecules has recently been
proposed by Trumpp-Kallmeyer et al . (1992) in which
catecholamine agonists interact with the binding
pocket at three conserved residues, consistent with ex-
isting mutagenesis data : an aspartate in TM3 and two
serines in TM5. A similar model has been indepen-
dently developed by our laboratory, specifically for the
D, dopamine receptor subtype. In both these models,
several hydrophobic, largely aromatic, residues are lo-
cated within the lumen of the receptor and project into
the vicinity of the putative catecholamine binding site .
Some of these residues are predicted to move on ago-
nist binding, potentially initiating conformational
shifts of the protein .
As an alternative to the models developed by
Trumpp-Kallmeyer et al . (1992) and by our laboratory,
a model proposed by Dahl et al . (1991) presents a
different perspective on D2 receptor topography and
function . The Dahl model is based on binding at aspar-
tate-80 in TM2 and asparagine-390 in TM7 of the rat
D, short isoform, equivalent to asparagine-418 of the
human D, long isoform, placing the dopamine mole-
cule deeper within the receptor core than is predicted
by binding at aspartate-114 . A few studies (Strader et
al ., 1987h, 1988 ; Horstman et al ., 1990 ; Neve et al .,
1991) indicate that these residues, or their cognates in
other seven-TM receptor subtypes, may indeed play
some role either in ligand binding or in allosteric regu-
lation of receptor conformation . Dahl et al . (1991)
hypothesized that signal transduction is due to disrup-
tion of electrostatic fields initiated by binding of a
protonated agonist near aspartate-80 ; no mention of
hydrophobic residues is made in this model .
The present study therefore was designed to test
the strength of such computer-generated models by
selectively mutating several hydrophobic residues that
are highly conserved among receptors of small cationic
ligands (for sequence comparison, see Trumpp-Kall-
tneyer et al ., 1992) and are predicted to participate in
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both stabilization of binding and the initiation of signal
transduction in several seven-TM subtypes . For this
particular study, the pharmacologically and function-
ally well-characterized D, receptor subtype was used .
The specific point mutations (Fig . 1) include three
phenylalanine residues hypothesized to stabilize the
binding of dopamine at aspartate-1 14, serine-194, and
serine-197 . Specifically, phenylalanine-389 in TM6
may electronically shield the electrostatic interaction
between the positively charged amine group of dopa-
mine and the negatively charged carboxyl group of
aspartate-1 14, and phenylalanine-198 in TM5 and phe-
nylalanine-390 in TM6 may stabilize the binding of
dopamine by interacting with the aromatic nucleus of
the catecholamine . According to the Trumpp-Kall-
meyer model, these phenylalanines must move to ac-
commodate the binding of dopamine and may therefore
participate in a cascade of conformational changes
leading to receptor activation . Two additional residues
not mentioned in the model of Trumpp-Kallmeyer et
al . (1992) were also mutated : phenylalanine-411 in
TM7 and leucine-387 in TM6. According to our model,
phenylalanine-411 and leucine-387 may also be in-
volved in signal transduction . In attempts to preserve
the tertiary conformation of the receptor, all replace-
ment mutations were made to alanine .
MATERIALS AND METHODS
Mutagenesis
A eDNA containing the entire coding region and
	
1,000
by of the 3' untranslated region of the long isoform of the
human D2 receptor was ligated into the eukaryotic expression
vector pCMVneo, which contains the SV40 origin ofreplica-
tion (pCMVD2L) . Transcription of the D2 receptor was
driven by the cytomegalovirus (CMV) promoter . A full-
length eDNA for the long isoform of the human D, receptor
was simultaneously subcloned into ml3mp18, which was
used to derive the single-stranded template for mutagenesis
reactions . Site-directed mutants were created using the Am-
ersham mutagenesis kit V2 .1 . Complementary, mutant oligo-
nucleotides of 24 bases were synthesized and purified twice
by HPLC . Mutants were verified by dideoxy chain termina-
tion DNA sequencing (Sequenase, V3 .0) . Mutated frag-
ments were then subcloned into pCMVD2L . A /3-galactosi-
dase eDNA construct was also created in pCMVneo for
transfection efficiency corrections (pCMV,6-gal ) .
Cell culture and transfection
COS-1 cells were maintained in Dulbecco's modified Ea-
gle's medium supplemented with 10% fetal bovine serum at
37 °C in 5% C02 /95% OZ and Subcultured every 3-5 days .
Cells were seeded at a density of 1-1 .5 X 10` cells per
10-cm-diameter dish for transfections . For receptor binding
assays, transfections were performed according to the cal-
cium phosphate precipitation protocol of Chen and Okayama
(1987), rising 20 Fig of pCMVD2L and 5 jig of pCMV/3-
gal for transfection efficiency corrections . Transfected cells
were incubated at 37 °C in 3% CO, for 18-24 h, following
which the cells were washed twice with Versene and once
with Dulbecco's modified Eagle's medium containing 10%
fetal bovine serum . Transfected cells were then returned to
FIG. 1. Schematized topography
of the long isoform of the human
D, dopamine receptor . Solid cir-
cles represent putative ligand
binding sites . Stippled circles rep-
resent residues mutated to alanine .
The specific mutants are labeled
with boxes.
incubation at 37 °C in 5% CO, for 24-48 h before receptor
binding and 0-galactosidase activity assays were performed .
For radioimtrnunoassay assessment of intracellular cyclic
AMP (CAMP) accumulation, COSA cells were transfected
by electroporation . One 10-cm-diameter dish of subconfluent
cells was washed in phosphate-buffered saline (PBS) and
then trypsinized (0.5% trypsin in 5.3 mM EDTA) for 2 min
at 37°C . Cells were then harvested and washed twice in
PBS at 0°C to remove the trypsin . The cellular pellet was
resuspended in 1 ml of PBS and electroporated with 5 pg
of pCMVß-gal and 20 Ng of either wild-type or mutated
pCMVD2L at 250 V and 330 pF at 0°C in disposable 1-ml
electroporation chambers using a BRL Cell-Porator system .
As a control, mock-transfected COS-1 cells were electropor-
ated with 5 Ng of pCMVß-gal. Electroporated cells were
allowed to recover at 0°C for 10 min before being diluted in
Dulbecco's modified Eagle's medium containing 10% fetal
bovine serum. The diluted cells were then aliquoted into 24-
well culture dishes and incubated at 37°C in 5% CO_, for
48-72 h before quantification of cAMP .
Radioligand binding assays
Cells transfected by the calcium phosphate method were
washed twice and harvested in either antagonist binding
buffer (50 mM Tris, 120 mM NaCl, 0.1% ascorbic acid, 5
mM KCI, and 5 mM MgCl,, pH 7.1 at 22°C) or agonist
binding buffer (50 mM Tris, 5 mM KCI, 5 mM MgCl2, and
I mMEDTA, pH 7.4 at 22'C) . Harvested cells were pelleted
at 500 g for 5 min, resuspended in binding buffer, and ho-
mogenized (Virtishear homogenizer ; 80% maximum rpm,
30 s) . For Scatchard analysis, cellular homogenates were
incubated with the D antagonist ['H]raclopride (specific
activity, 75 .1 Ci/mmol ; Du Pont/NEN) or ['H]spiperone
(specific activity, 17 .7 Ci/mmol; Du Pont/NEN) or the DZ
agonist ['H]N-0437 (specific activity, 105 Ci/mmol; Amer-
sham) at six to eight concentrations . Nonspecific binding
was determined by displacement with the DZ antagonist (+)-
butaclamol (I NM) . The total volume in each incubation
reaction was 250 pl per tube. Incubations were performed
in duplicate for 60 min at 22°C . For the generation of compe-
tition isotherms, cellular homogenates were incubated in the
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presence of saturating concentrations of I'HIspiperone ( 1-
5 n M) displaced by increasing concentrations of unlabeled
agonist [R(-)-propylnorapomorphine (NPA), apoinor-
phine, 2-bromo-a-ergocryptine (bromocriptine), or dopa-
mine . The total volume in each incubation reaction was
240 p1 per tube . Incubation reactions were performed in
duplicate at 22°C for 60-90 min. K values from Scatchard
plots and K, values from competition curves were determined
by using LIGAND (Munson and Rodbard, 1980) (version
4.0 for the Macintosh) and averaged from a minimum of
two isotherms.
Quantification of CAMP
Dulbecco's modified Eagle's medium containing 10% fe-
tal bovine serum was aspirated from 24-well culture dishes
containing COS-1 cells electroporated with either wild-type
or mutated pCMVD2L and replaced with Dulbecco's modi-
fied Eagle's medium . Cells were then preincubated with 0.5
mM 3-isobutyl-l-methylxanthine, 10 pM SCH-23390 (to
prevent any D,-mediated effects), and 10 N,M (-)-alpreno-
lol (to prevent any adrenergic effects) for 30 min at 37°C
before incubation with 50 pM forskolin, at which time vary-
ing concentrations of either dopamine or bromocriptine were
applied for 15 min at 37°C . The drubcontaining medium
was then quickly removed by aspiration . Each well was
washed twice with ice-cold PBS and then lysed in 65%
ethanol for 8-12 h at 4°C. The lysate was collected, centri-
fuged at 2,000 g for 15 min, and lyophilized . The lyophilized
cAMP extract was resuspended and diluted in 0.05 M sodium
acetate (pH 6.2), and the amount of cAMP was assessed by
equilibrium radioimmunoassay . Triplicate tubes of resus-
pended cAMP were incubated with anti-cAMP antiserum
(Sigma Immunochemical) for 4 h at 4°C. -'l-cAMP tracer
was then added to each tube. Tubes were quickly vortex-
mixed and incubated for an additional 18-24 h . Antigen/
antibody complexes were coprecipitated with bovine serum
albumin (fraction V; Sigma) in ethanol, by centrifugation
at 2,000 g for 15 min at 4°C. The supernatant was aspirated,
and the remaining pellets were assayed for undisplaced' z51-
cAMP using a GammaTrac 1290/TM analytical -y-radiation
counting system . The amount of cAMP in each tube was




0.061 ±- 0.002 0.40 ± 0.05
L387A 0.085 ± 0.008 0.40 ± 0.06
Data are mean ± SEM K values (n = 2-3) from two or three
Scatchard plots for wild-type and mutant (F198A, phenylalanine-
198 -" alanine ; F389A, phenylalanine-389 - alanine ; F390A, phe-
nylalanine-390 - alanine ; F41 1A, phenylalanine-41 1 -+ alanine; and
L387A, leucine-387 - alanine) DZ receptors. NSB indicates that no
specific binding was measurable .
determined by comparison with a standard curve of known
concentrations of unlabeled cAMP. All cAMP level mea-
surements were determined from six to nine independent
experiments .
Western immunoblot assay
COS-1 cells transfected with 25 yg of either the wild-
type or mutant pCMVD2L by calcium phosphate precipita-
tion were scraped off and stored as loose pellets until electro-
phoresis . Cells were resuspended in deionized water, and an
aliquot containing 30 pg of total protein was diluted in a 2X
loading buffer [24.8 mM Tris base, 192 mM glycine, and
0.1% (wt/vol) sodium dodecyl sulfate] and boiled for 5
min. The proteins were electrophoresed through a sodium
dodecyl sulfate/10% polyacrylamide resolving gel using a
BRLMini-V 8 .10 Vertical Gel Electrophoresis System. Pro-
teins were then transferred to a nitrocellulose membrane in
transfer buffer (24.8 mM Tris base, 192 mM glycine, and
10% methanol) for -2 h at 0°C and 150 V. The membrane
was incubated in a blocking buffer of 1% nonfat powdered
milk in PBS for 1 h with gentle agitation at 22°C, washed
three times in PBS, and incubated overnight at 22°C with a
1 :5,000 dilution of rabbit anti-D 2 antiserum raised against
the third cytosolic region (amino acids 246-316) of the long
isoform of the human D2 receptor . The membrane was then
washed three times in PBS and incubated with goat IgG
directed against rabbit IgG for 1 h at 22°C . The membrane
was again washed three times in PBS and incubated with a
Data are mean - SEM K and K; values (n = 2-4) from two to four isotherms for wild-type and mutant (F198A, phenylalanine-198 -
alanine; F389A, phenylalanine-389 - alanine; F41 I A, phenylalanine-41 1 - alanine ; and L387A, leucine-387 - alanine) D= receptors . In
competition experiments, [ 3H]spiperone was used as the labeling ligand . NSB indicates that no specific binding was detectable . K, values for
mutant F390A (phenylalanine-390 - alanine) could not be measured because this mutant did not display any specific binding for the labeled
ligands .
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TABLE 1 . Antagonist binding
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TABLE 2. Agonist binding
rabbit anti-horseradish peroxidase antibody for 1 h at 22°C .
After washing in PBS, the membrane was then incubated in
horseradish peroxidase (4 pg/ml) for 1 h at 22 °C. Following
the final washes in PBS, the membrane was added to a
diaminobenzidine substrate solution [20% (wt/vol) 3,3'-
diaminobenzidine, 63 mM nickel ammonium persulfate, and
0.0005% HZOZ in PBS J . The color reaction was terminated




The long isoform of the wild-type human D2 recep-
tor and five individual substitution mutations (F198A,
F389A, F390A, F41 ]A, and L387A) were character-
ized by their abilities to bind two D_-specific antago-
nists in saturation binding experiments and five ago-
nists in saturation and competition assays (Tables 1
and 2) . The mutant and wild-type D= constructs, when
transiently transfected into COS-1 cells by calcium
phosphate precipitation, produced high levels of recep-
tor binding as detected by the antagonist [3H]-
spiperone (ranging from 0.3 to 1 .5 pmol/mg of pro-
tein) except for mutant F390A, which was unable to
bind any labeled ligand used in this study ([ 3H]-
spiperone, [3H] raclopride, or [3H J N-0437) . The pres-
ence of D2-like immunoreactive protein in transfected
COS-1 cells was verified by western blot analysis . A
predominant band at -42 kDa was observed in cells
transfected with the wild-type D= and all mutants, in-
cluding F390A, but not in untransfected COS-1 (data
not shown) . In addition, transfection efficiencies were
estimated by expression of the cotransfected ß-galac-
tosidase reporter construct, which demonstrated similar
efficiencies across mutants (data not shown) . Scatch-
ard analysis using the labeled agonist [ 3H] N-0437 pro-
duced K values in the nanomolar range; K values
for the antagonists [ 3H]spiperone (Fig . 2) and [ 3 H]-
raclopride were in the picomolar and nanomolar
ranges, respectively . Agonist competition of ['H]-
spiperone produced the following rank order of po-












D, wild-type 1 .7 ± 0.58 8.2 - 2.0 22 ± 12 200 -± 162 1 .0 ± 0.40
F198A NSB 6.3 - 2.7 23-15 39-13 1 .6-1 .1
F389A NSB 850 ± 642 7,200 ± 6,800 16,000 ± 740 59 { 55
F390A NSB
F41 IA 1 .2-0.045 6.6±0.02 25 - 4.9 250 ± 134 0.89 - 0.40
L387A 1 .2 ± 0.065 5.9 ± 2.2 34-9.4 220± 177 10±0.87
Receptor ['HISpiperone (nM) ['H]Raclopride (nM)
D2 wild-type 0.083 ± 0.009 0.98 - 0.14
F198A 0.091 ±0.010 1 .4±0.28
F389A 2.8 -! 0.84 NSB
F390A NSB NSB
FIG. 2 . Representative Scatchard plots of [3H]spiperone bind-
ing for (A) the wild-type D2 receptor and (B) replacement of
phenylalanine at position 389 with an alanine (mutant F389A) .
Nonspecific binding was determined with 1 jiM (+)-butaclamol .
> apomorphine > dopamine (Table 2 and Fig . 3) .
Specific results of binding experiments with the vari-
ous mutants are detailed below and in Tables 1 and 2
and Figs . 2 and 3 .
F1 98A . Mutation of phenylalanine-198 to alanine in
TM5 (F198A) exhibited antagonist binding character-
istics essentially unchanged from those of the wild-
type D2 (Table 1) . Affinities for the D2 agonists bro-
mocriptine, NPA, apomorphine, and dopamine were
also relatively unaffected (Table 2 and Fig . 3) ; how-
ever, no specific binding for the agonist [ 3H]N-0437
could be measured .
F389A and F390A . Individual mutations of phenyl-
alanine-389 to alanine (F389A) and phenylalanine-390
to alanine (F390A), both in TM6, produced dramatic
effects on binding to both antagonists and agonists
(Tables 1 and 2) . Specific binding was detectable for
F390A neither to the agonist [ 3H]N-0437 nor to
the antagonists [ 3H]spiperone and [ 3H]raclopride .
F390A's failure to bind any labeled ligand used in this
study precluded further pharmacological characteriza-
tion of this mutant . Saturation binding experiments
with F389A produced similarly dramatic KL, changes ;
specific binding was not detectable to the agonist
1 3H ] N-0437 or to the antagonist [ 3H ] raclopride . How-
ever, F389A was able to bind [ 3H] spiperone, but with
a 34-fold decreased affinity, as compared with the
wild-type D, (Fig . 2) . Competition isotherms for
F389A, using [ 3H]spiperone as the labeled ligand,
demonstrated dramatic shifts in K; values (59-327-
fold) for binding with the agonists bromocriptine, apo-
morphine, NPA, and dopamine (Fig . 3) .
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L387A and F411A . In saturation studies, the indi-
vidual mutations of phenylalanine-411 to alanine
(1741 IA) in TM7 and leucine-387 to alanine (L387A)
in TM6 demonstrated no appreciable changes in bind-
ing affinities for the antagonists [ 3H]spiperone and
[ 3H]raclopride or to the agonist [ 3H]N-0437 (Tables
1 and 2) . For the most part, competition isotherms
with agonists produced similarly undramatic shifts in
K; values (Table 2 and Fig . 3) with one exception :
Mutant L387A produced a 10-fold decrease in affinity
for dopamine.
Effect of mutations on intracellular CAMP
accumulation
The wild-type D2 receptor and the D2 mutants
(F198A, F389A, F390A, F41 1A, and L387A) were
tested for their ability to inhibit forskolin-stimulated
accumulation of intracellular cAMP by incubation with
the D2 agonist dopamine or bromocriptine in electro-
porated COS-1 cells . Electroporation, in contrast to
transfection by calcium phosphate precipitation, yield-
ed much higher transfection efficiencies, based on 8-
galactosidase transfection efficiency estimates (70-
90% of all cells by electroporation in comparison with
5-15% by calcium phosphate) . As a result, electropor-
ation was the transfection method of choice for per-
forming functional assays . Dose-response curves de-
rived from either the wild-type D2 receptor or the mu-
tant F198A were biphasic for the agonists dopamine
and bromocriptine (Fig . 4) . The wild-type D2 pro-
duced statistically significant inhibition of forskolin-
stimulated cAMP accumulation between 20 nM and 2
p.M dopamine (Fig . 4) . This inhibition was maximal
(49%) at 20 nM dopamine (Table 3) . The wild-type
DZ also demonstrated significant inhibition at 3 and
10 nM bromocriptine, maximally by 62% at 10 nM
bromocriptine . Inhibition by F198A reached 25% for
dopamine at 200 nM dopamine and 55% for 10 nM
bromocriptine (Table 3 and Fig . 4) . However, at
higher dopamine or bromocriptine concentrations, the
inhibition was attenuated in a dose-dependent manner .
The mutants F389A, F411 A, and L387A did not dis-
play discernible dose-response curves for dopamine
(n = 7) or for bromocriptine (n = 6) . This impaired
inhibition could not be explained simply by lack of
expression due to electroporation . Receptor levels for
F198A, F389A, F41 IA, and L387A were similar to
those obtained with the wild-ty pe D2 (200-500 fmol/
mg of protein) ; electroporated F390A was not detect-
able by [ 3 H] spiperone binding . F390A did not display
statistically significant inhibition by bromocriptine but
did demonstrate 33% inhibition at 2 pM dopamine
(Table 3 and Fig . 4) .
DISCUSSION
The results from mutations of hydrophobic residues
within the putative TM regions of the D2 dopamine
receptor demonstrate that single amino acid changes
J . Nem-oehem., Vol. 65, No . 5, 1995
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can markedly affect binding and signal transduction
properties of this seven-TM receptor . Two TM6 phe-
nylalanine mutants, F389A and F390A, bound ligands
very poorly . In contrast, mutants in the TM7 phenylala-
nine (17411 A) and the TM6 leucine (L387A) displayed
pharmacological profiles similar to that of the wild-
type D2 . The TM5 mutant F198A exhibited relatively
high affinity for most of the ligands tested but dis-
played no specific binding for the agonist [ 3H ] N-0437 .
When analyzed for functional characteristics, i .e ., abil-
ities to inhibit cAMP accumulation when stimulated
with agonists, it was clear for all the mutants except
for F198A that signal transduction was impaired to
some degree . For all mutants, however, western analy-
sis suggests that a receptor of the correct molecular
weight was expressed. Because F389A and F390A dis-
played poor binding as well as poor signal transduc-
tion, it is difficult to assess whether the diminished
functional capacities of these particular mutants were
secondary to binding affinity changes or to entirely
different mechanisms . Although the functional deficits
of F389A and F390A may have been predicted from
their poor binding affinities to agonists, it is interesting
that it proved not to be the case that the mutants that
J. Neurochern., Vol. 65, No. 5, 1995
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FIG . 3 . Representative competition bind-
ing assays for (A) wild-type D2 , (B) mutant
F1 98A (phenylalanine-198 - alanine), (C)
mutant F389A (phenylalanine-389 - ala-
nine), (D) mutant F411A (phenylalanine-
411 -> alanine), and (E) mutant L387A
(leucine-387 -> alanine) receptors . Satu-
rating concentrations of [ 3 H]spiperone
were displaced by bromocriptine, NPA,
apomorphine, and dopamine . Data are not
presented for mutant F390A (phenylala-
nine-390 - alanine) because this mutant
was unable to bind any labeled ligand
used in this study .
successfully bound agonists were necessarily the same
mutants that inhibited adenylyl cyclase ; that is, a non-
identity between binding and signal transduction was
observed in mutants F41 IA and L387A . F41 IA and
L387A retained high affinities to agonists but were
unable to inhibit adenylyl cyclase . These mutants are
most interesting as minor structural changes have high-
lighted separately the binding and signal transduction
functions of the D, receptor .
The wild-type DZ receptor, when analyzed for bind-
ing characteristics, produced a typical D--like pharma-
cological profile. When analyzed for functional charac-
teristics, the wild-type receptor produced an unex-
pected biphasic response to agonist dose . It has been
amply demonstrated that the Dz receptor is able to
inhibit adenylyl cyclase activity (De Camilli et al .,
1979 ; Albert et al ., 1990), and measurement of intra-
cellular cAMP level changes demonstrates that in this
experimental paradigm, the agonists dopamine and
bromocriptine were able to inhibit elevated intracellu-
lar CAMP levels in COS-1 cells transiently transfected
with the wild-type DZ receptor . Both agonists were
able to inhibit CAMP accumulation maximally by
-50-60% . It is interesting that the inhibition curves
were not sigmoidal but rather U-shaped . This biphasic
pattern was very reproducible . Similar responses in
adenylyl cyclase activity have been reported in Chinese
hamster ovary cells transfected with variants of the a2 -
adrenergic receptor (Eason et al ., 1992) and by m4-
muscarinic acetylcholine receptors, also transfected
into Chinese hamster ovary cells (Jones et al ., 1991) .
Both the a2-adrenergic receptor and the m4-muscarinic
acetylcholine receptors, like the D, dopamine receptor,
have been traditionally categorized as G;-coupled. Fed-
erman et al . (1992) have reported that stimulation of
D2 receptors expressed in COS-7 cells increases ade-
nylyl cyclase activity when these cells are cotrans-
fected with a mutationally active a subunit of Gs; the
"conditional" stimulation is thought to be due to acti-
vation of type 11 adenylyl cyclase by /3y subunits re-
leased from G; . The study by Eason et al . (1992) sug-
gests that the stimulatory arm of the biphasic curve is
due to direct coupling with Gs , as a result of overex-
pression of the recombinant receptors . In the present
study, attenuation of adenylyl cyclase inhibition at high
agonist doses may similarly be due to overexpression
of the D, receptor, either causing a "spillover" cou-
pling with Gç , which acts to increase adenylyl cyclase
activity, or allowing G;-released /ßy subunits to stimu-
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FIG. 4. Dose-effect curves for stimulation with either dopamine (n = 7) or bromocriptine (n = 6) : (a) D2 wild-type, (b) F198A
(phenylalanine-198- alanine), (c) F390A (phenylalanine-390 -i alanine) with dopamine, (d) D2 wild-type, and (e) F198A with bromocrip-
tine . Data are mean ± SEM (bars) values at each agonist dose as percentages of the stimulated state without agonist (50 p.M forskolin
+ 0.5 mM 3-isobutyl-l-methylxanthine) . Other mutants did not produce statistically significant dose effects. "Significance by Fisher
PLSD post hoc analysis of one-factor ANOVAs at 95% .
late conditionally adenylyl cyclase . The mechanism
and physiological relevance of this phenomenon have
yet to be determined. Using the binding profile and
functional characteristics of the wild-type DZ receptor
as reference standards, the properties of the mutated
receptors were assessed and are described in detail
below .
F198A
Phenylalanine-198, located in TM5, is hypothesized
to stabilize binding through Jr- 7 interactions with the
aromatic nucleus of the endogenous catecholamine li-
gand dopamine . Yet replacement of this aromatic
group with the methyl group of alanine only disrupted
binding of the agonist ['H]N-0437, whereas the bind-
ing of other ligands remained essentially unaffected .
These data suggest that if phenylalanine-198 does offer
a stabilizing influence, its absence is not detected by
the binding of most dopaminergic ligands . In other
words, all aromatic ligands may not depend on this
particular influence to the same degree . The differential
effects are not surprising given that the molecular
structures of the ligands tested vary widely . Alterna-
tively, phenylalanine-198 may be highly conserved
owing to a generalized structural role that does not
affect the nature of the binding pocket .
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'FABLE 3 . Maximal inhibition Qf cAMP accumulation by
dopamine and bromocriptine
1 . Ncuro, hem., Vol. 6 .5, No. .5, 1995
Intracellular levels of cAMP were elevated with 50 pM forskolin
and 0 .5 in Al 3-isobutyl-I-methylxanthine in COS-I cells transfected
with wild-type and mutant (F198A, phenylalanine-198 - alanine ;
F389A, phenylalanine-389 - alanine ; F390A, phenylalanine-390 -
alanine ; F41 IA, phenylalanine-411 - alanine ; and L387A, leucine-
387 -alanine) D, receptors . Mean ± SEM inhibition ofthis accumu-
lation (n = 6-9) is reported at 10 nM bromocriptine, the dose that
produced maximal inhibition in the wild-type D, and mutant F198A .
and at indicated doses of dopamine. Dashes indicate no significant
inhibition when analyzed by one-factor ANOVA at 95% .
Mutant F198A was able to bind dopamine and bro-
mocriptine with wild-type D2-like affinities and ac-
cordingly demonstrated near wild-type functional char-
acteristics when stimulated with these agonists . Both
the models generated by Trumpp-Kallmeyer et al .
(1992) and by our laboratory predict the importance
of the TM5 phenylalanine-198 for both binding stabili-
zation and receptor activation . However, the pharma-
cological profile of F198A was largely unchanged, and
inhibition of adenylyl cyclase activity did not appear
to be dramatically affected, although maximal inhibi-
tion by dopamine may have been reduced somewhat .
It is interesting to note that the dose-response profiles
of F198A were also biphasic . Thus, at least with re-
spect to the agonists dopamine and bromocriptine, it
appears that the bulk and aromatic properties of phe-
nylalanine-198 are not overtly important for agonist-
induced signal transduction or for stabilization of bind-
ing as originally predicted . However, the functionally
intact appearance of F198A does not rule out the poten-
tial role of phenylalanine-198 in signal transduction .
The models tested in this study implicate several other
hydrophobic side chains in receptor activation, as men-
tioned in the introductory section . It is conceivable that
a ligand as large as the ergot derivative, bromocriptine,
is able to trigger critical conformational changes by
interacting with multiple, parallel triggering mecha-
nisms that remain intact in F198A . In addition, the
slightly reduced maximal inhibition by dopamine
(25% vs . 49% for the wild-type DZ) and the narrower
range of doses that produced significant inhibition may
indicate some reduction in signal transducing capabili-
ties induced by the endogenous ligand . To characterize
this mutant completely, functional assays using N-
0437 would be desirable because the altered binding
affinity for [3H]N-0437 in the absence of similar
changes for other agonists suggests the existence of
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some specific interaction between this particular mole-
cule and phenylalanine-198 . Unfortunately, this ago-Z,
was not available in the unlabeled form .
F389A and F390A
Of the hydrophobic residues mutated in this study,
it appears that the conserved phenylalanines at posi-
tions 389 and 390 in TM6 are most critical for binding
to both agonists and antagonists . The importance of
the phenylalanine residue at position 389 is demon-
strated by the severely altered binding profile of the
DZ receptor when this amino acid was mutated to an
alanine . Computer-generated models of the D, receptor
set forth by Trumpp-Kallmeyer et a] . (1992) and by
our laboratory predict that this conserved residue forms
part of a hydrophobic pocket that stabilizes the electro-
static interactions between the negatively charged TM3
aspartate-l 14 and the positively charged head group
of dopamine . Based on these models, one would expect
that alteration of this stabilizing pocket would alter
binding of any ligand that utilizes this binding site .
The presently reported binding profile is constructed
of five agonists and two antagonists ; the binding affin-
ities to all of these ligands were reduced, suggesting
the "universal" use of the binding site at aspartate-
l 14 stabilized by phenylalanine-389 . Similar to the
dramatic binding changes observed on mutation of
phenylalanine-389, mutation of phenylalanine-390 to
an alanine disrupted binding of the DZ receptor to the
agonist [3H ] N-0437 and the antagonists [ 3H ] rac-
lopride and ['H]spiperone to such a degree that no
specific binding could be observed for either of these
ligands . The importance of this phenylalanine for bind-
ing is supported by mutation of the equivalent residue
in /3-adrenergic (Dixon et al ., 1988) and the serotonin
5-HT, (Choudhary et al ., 1993) receptors . Unlike phe-
nylalanine-389, which may shield the interaction be-
tween aspartate-1 14 and positively charged groups of
the ligands, phenylalanine-390 may interact with the
aromatic nucleus of catecholamines . Although the pre-
dictions governing binding stability were originally
modeled on catecholamine binding, these predictions
are applicable to the agonist [3H]N-0437 and the an-
tagonist [ 3 H]raclopride, because both ligands contain
an aromatic core, and both appear to utilize binding
sites at the D, receptor similar to those used by dopa-
mine (Mansour et al ., 1992) . Although the alterations
in binding may be due to loss of stabilizing influences,
the phenylalanines at positions 389 and 390 are located
very close to a proline residue at position 388, and
binding shifts may be due to local alterations in protein
conformation about this potential "hinge" site (Brand)
and Deber, 1986) .
The replacement of the large aromatic TM6 phenyl-
alanines not only disrupted binding but also signal
transduction . Mutants F389A and F390A were unable
to demonstrate significant inhibition of cAMP accumu-
lation when stimulated with bromocriptine. These re-






Wild-type D, 49 ± 8% (20 nM) 62 ± 15%
F198A 25 ± 11% (200 nM) 55 ±- 10%
F389A - -
F390A 33 + 14% (2 PM) -
F41 IA - -
L387A - -
binding affinity of F389A for bromocriptine (K; = 850
nM, compared with 8 .2 nM for the wild-type D2) and
the presumably poor affinity of F390A for this ligand .
The impaired receptor function observed on bromo-
criptine stimulation is most likely due to impaired
binding to these mutants . Similarly, F389A was unre-
sponsive to dopamine. It is surprising that F390A,
which was presumed unable to bind any agonists, was
capable of inhibiting CAMP accumulation when stimu-
lated with the endogenous ligand dopamine, although
only at a much higher concentration . Dopamine bind-
ing with F390A could not be directly assessed owing to
this mutation's inability to bind any radioligand tested ;
however, in light of these functional data, it must be
assumed that this mutant is capable of some binding
with dopamine .
The results obtained from F389A and F390A are in
some disagreement with the results of a recent muta-
genesis study in the 5-HT2 receptor subtype in which
mutation of phenylalanine-340 (equivalent to phenyl-
alanine-390 in the human D2) to a leucine diminished
binding of several antagonists and agonists and also
diminished functional coupling to phosphoinositide
hydrolysis, whereas mutation of phenylalanine-339
(equivalent to the DZ phenylalanine-389) to leucine
had less dramatic effects on binding and virtually no
effect on 5-HTZ receptor coupling (Choudhary et al .,
1993) . The present study indicates that mutation of
either one of these highly conserved phenylalanines
significantly disrupts D2 binding and function, more
so for phenylalanine-389 than phenylalanine-390 . The
5-HTZ receptor mutations, however, were made to leu-
cine, thus preserving the bulk of the substituted resi-
dues while eliminating their aromaticity . By examining
the results of the 5-HTZ receptor mutations together
with those of the present study, it seems that the size
and hydrophobicity, rather than the aromaticity, of phe-
nylalanine-389 (or phenylalanine-339 in the 5-HTZ )
are important for proper ligand binding and signal
transduction, whereas the aromaticity of phenylala-
nine-390 (phenylalanine-340 in the 5-HT, receptor)
appears critical for stabilization of ligand binding and
for signal transduction . Alternatively, the stabilizing
role of phenylalanine-389 may not be conserved be-
tween dopaminergic and serotonergic receptors, be-
cause these receptor families bind different classes of
small molecules, i .e ., catecholamines and indole-
amines, respectively . Both classes of ligands possess
a positively charged amine group that presumably
binds to the TM3 aspartate-114 of D2 or its serotoner-
gic equivalent . But whereas catecholamines appear to
utilize the two hydroxyl groups of the catechol moiety
for binding to two TM5 serines (Mansour et al ., 1992),
indoleamines have only the hydroxyl group, which po-
tentially binds to only one TM5 serine (Trumpp-Kall-
meyer et al ., 1992) . Thus, the slight variation in ligand
anchor points may produce variation in the importance
these TM6 phenylalanines . In both receptor families,
however, it is clear that replacement of either of these
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conserved phenylalanine residues in TM6 disrupts
ideal binding and function of the receptor, perhaps by
eliminating stabilizing stacking interactions with the
ligand or by altering the native conformation of the
receptor .
F411A and L387A
The TM7 phenylalanine at position 411 and the TM6
leucine at position 387 were not residues predicted to
be important for ligand binding stabilization . Accord-
ingly, replacement of phenylalanine-41 1 with an ala-
nine (F411A) failed to produce dramatic changes in
the wild-type binding affinities to various antagonists
and agonists . Similarly, uninteresting changes were ob-
served for the replacement of leucine-387 with alanine
(L387A) except for a modest (10-fold) increase in the
K; value for dopamine . Binding with dopamine may
have been less than optimal owing to subtle changes
in receptor conformation caused by the replacement
of the large branched chain of leucine-387 with the
relatively small methyl group of alanine . If the immedi-
ately adjacent proline-388 represents a critical point of
flexure for maintaining optimal receptor conformation,
a change in the adjacent conformational space may
have produced slight changes in the tertiary structure
of the protein to which only the endogenous ligand,
dopamine, is sensitive .
Although replacement of the bulky side chains of
phenylalanine-41 I and leucine-387 did not dramati-
cally affect ligand binding, these mutated residues
proved to be critical for signal transduction through
the G;/adenylyl cyclase pathway . Neither dopamine
nor bromocriptine was able to inhibit adenylyl cyclase
through either of these mutants despite their high-af-
finity binding to these agonists . Thus, single amino
acid substitutions within either the sixth or seventh
transmembrane helices apparently uncoupled ligand
binding from signal transduction . Although both the
TM7 phenylalanine-411 and the TM6 leucine-387 are
suspected to be involved in a common conformational
shift of the entire protein, the "micromechanisms" by
which these mutations disrupt receptor activation are
probably different . Computer modeling performed in
our laboratory suggests that, on agonist binding, phe-
nylalanine-411 may move owing to steric interactions .
It is conceivable that removal of this particular TM7
phenylalanine could eliminate sterically induced shifts
in the position of the seventh TM helix and, as a conse-
quence, the position of the carboxyl-terminal tail, a
region shown to be involved in G protein coupling
(Dixon et al ., 1988 ; Cotecchia et al ., 1990) . In con-
trast, the leucine at position 387 of TM6 probably does
not move in response to steric influences . Instead, this
residue may be an important influence on the "hinge"
action of the adjacent proline at position 388 . Prolines
are exceptional not only for placing kinks in a-helices,
but possibly also for providing membrane proteins with
natural hinges (Brandl and Deber, 1986) owing to the
relatively high probability of trans/cis isomerization
.1 . Neurochem., Vol . 65, No . 5, 1995
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about the X-proline peptide bond, where X is any
amino acid to the N-terminal side (Brandts et al .,
1975) . There is some evidence that the residue imme-
diately preceding proline may affect this isomerization
because the bulky pyrrolidine ring restricts the confor-
mational space of the preceding amino acid (Brandts et
al ., 1975) . Replacement of the large branched leucine
residue with the small, hydrophobic methyl group of
alanine changes the steric environment near the adja-
cent proline and may affect not only its isomerization
but also the motion of the entire sixth TM barrel . It is
not difficult to believe that a critical hinge motion of
TM6 is involved in receptor activation and G protein
coupling because this helix is directly linked to the
third cytosolic loop of the receptor protein .
It is interesting that replacement of any single one
of these residues (phenylalanine-41 1 and leucine-387)
with an alanine was sufficient to impair coupling . The
simplest explanation for these observations is a linear
or chain-like arrangement of steps involving phenylal-
anine-411 and leucine-387 (and also possibly phenyl-
alanines at positions 389 and 390) in which removal
of any one of the "links" would block the propagation
of conformational changes . However, one cannot rule
out the possibility that these residues may individually
be involved in disparate pathways leading to a common
activated receptor conformation .
Conclusions
To summarize the present study, mutations of sev-
eral hydrophobic amino acids in the TNI domains of
the human D, receptor, long isoform, were constructed
and characterized . The mutated residues were chosen
based on computer-generated models devised by our
laboratory and that of Trumpp-Kallmeyer et al . (1992)
that predicted their importance in binding and signal
transduction . Such computerized models serve as ex-
cellent tools for visualizing the receptor protein and
providing starting points for mutagenesis studies .
However, the present study produced some interesting
details of the D, receptor that could not have been
completely predicted from the tested models . Perhaps
the most mundane interpretations would have arisen
from mutations that simultaneously disrupted agonist
binding and inhibition of adenylyl cyclase activity
(such as F389A) or mutations that significantly altered
neither of these receptor-mediated events (such as
F 198A ) . From the results presented, however, one ob-
serves that single amino acid mutations were able to
separate ligand binding events from the ultimate signal
transduction event . As cases in point, the mutants
F41 1 A and L387A were capable of binding dopamine
and bromocriptine with near wild-type affinities, yet
they were unable to demonstrate functional coupling.
Previous site-directed mutagenesis studies have suc-
cessfully elaborated regions of the receptor critical for
ligand binding and regions important for coupling with
G proteins . However, before a complete understanding
of seven-TM receptor function may be achieved, fur-
1. Nenro, hem ., Vol . 05, M, . 5 . 1995
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ther mutagenesis efforts with the aid of computer mod-
eling, such as the study reported here, must be aimed
at disclosing mechanisms linking these events .
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